Bayesian Capital Management LP Takes Position in GSK plc (NYSE:GSK)

Bayesian Capital Management LP acquired a new position in shares of GSK plc (NYSE:GSK - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,037 shares of the pharmaceutical company's stock, valued at approximately $475,000.

Several other hedge funds have also recently bought and sold shares of GSK. Indiana Trust & Investment Management Co lifted its position in GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after acquiring an additional 500 shares during the last quarter. Crews Bank & Trust acquired a new stake in GSK during the fourth quarter worth approximately $26,000. ST Germain D J Co. Inc. increased its holdings in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 522 shares during the period. Sierra Ocean LLC bought a new position in shares of GSK during the fourth quarter worth approximately $32,000. Finally, Parkside Financial Bank & Trust increased its holdings in shares of GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 818 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

GSK traded up $0.55 during midday trading on Monday, hitting $37.17. The stock had a trading volume of 2,495,470 shares, compared to its average volume of 4,778,430. The company has a market cap of $76.69 billion, a P/E ratio of 23.39, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The business has a fifty day moving average of $37.65 and a 200 day moving average of $35.97. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.43 earnings per share. As a group, equities analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.54%. GSK's dividend payout ratio (DPR) is presently 86.60%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, BNP Paribas began coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a strong buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and an average target price of $40.58.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.